Online inquiry

IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9732MR)

This product GTTS-WQ9732MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Hunter syndrome research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001128148.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7037
UniProt ID P02786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9732MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7024MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ15876MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ11917MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ2852MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ15583MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ893MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ14449MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ1855MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW